Meta-analysis of novel therapies for follicular lymphoma progression within 24 months shows high response rates.
New treatments show high response rates for advanced follicular lymphoma patients
This systematic review and meta-analysis evaluated outcomes for patients with follicular lymphoma experiencing disease progression within 24…
New powerful medicines help 91% of advanced follicular lymphoma patients whose disease returned quickly after treatment.
TACE plus camrelizumab and rivoceranib prolongs progression-free survival versus TACE alone in unresectable HCC
Combination therapy extends time without cancer progression in liver cancer patients
This phase II randomized trial in 200 patients with unresectable hepatocellular carcinoma compared TACE plus camrelizumab and rivoceranib (T…
Adding two new drugs to standard liver cancer treatment helped patients go 10.8 months longer without their cancer getting worse compared to…
Durvalumab plus chemotherapy improves event-free and overall survival in muscle-invasive bladder cancer compared to chemotherapy alone.
New treatment approach improves survival for advanced bladder cancer patients before surgery
This randomized, phase III, open-label trial evaluated neoadjuvant and adjuvant durvalumab combined with gemcitabine and cisplatin versus ge…
Adding an immune drug to standard chemotherapy before bladder surgery helps patients stay cancer-free longer and live longer than older trea…
Ultrasound-guided interventional therapy shows higher effectiveness and fewer adverse reactions than laparoscopic cyst resection for ovarian endometriosis cysts.
Ultrasound-guided therapy may work better and safer than surgery for ovarian cysts
This meta-analysis evaluated ultrasound-guided interventional therapy versus laparoscopic cyst resection in patients with ovarian endometrio…
Ultrasound-guided therapy may work better and safer than surgery for ovarian cysts, offering less pain and faster recovery for women.
Meta-analysis links rare APOB variants to advanced MASLD, cirrhosis, and hepatocellular carcinoma across large cohorts
Do rare gene changes linked to liver disease also raise your risk for cancer and scarring?
This meta-analysis reviews data from the Million Veteran Program, UK Biobank, and clinical cohorts to assess rare APOB variant carriage in p…
Rare gene changes linked to fatty liver disease also raise your risk for liver cancer and severe scarring, according to new findings.
Sequential cetuximab-bevacizumab vs bevacizumab-EGFR mAb shows no DDC difference in metastatic CRC
New Drug Order Doesn't Beat Old Standard
A phase III randomized controlled trial in 263 untreated, unresectable wild-type RAS/BRAF metastatic colorectal cancer patients found no dif…
A new drug order for advanced colon cancer did not improve disease control or survival compared to the standard treatment sequence.
Oscillating abrasive device matches curettage and sandpaper for AK skin prep before ADL-PDT
New Tool Makes Sun Damage Treatment Faster
In 22 patients with actinic keratoses undergoing artificial daylight photodynamic therapy, a novel oscillating abrasive skin preparation dev…
This new device makes treating rough sun spots quicker and more comfortable without losing effectiveness.
Becotatug vedotin shows 20.9% objective response in recurrent head and neck squamous cell carcinoma after prior therapy
For patients with advanced head and neck cancer, a new drug showed a 21% response rate in early testing.
This multicenter, Phase IIa trial evaluated intravenous becotatug vedotin in 67 patients with recurrent or metastatic squamous cell carcinom…
A new drug shrank tumors in 21% of patients with advanced head and neck cancer who had run out of standard treatment options.
Case report and literature review on concurrent t-AML and LNTB treated with chemoimmunotherapy
Two Rare Diseases Strike After Lung Cancer Treatment
This case report and literature review describes the management of a 54-year-old male with locally advanced lung squamous cell carcinoma, th…
A lung cancer patient treated with chemo and immunotherapy developed two rare diseases simultaneously: a new blood cancer and tuberculosis.
Prolonged nightly fasting plus telehealth coaching showed feasibility in men with prostate cancer on androgen deprivation therapy.
Can fasting and coaching help men with prostate cancer feel better and manage weight?
This pilot randomized controlled trial assessed a prolonged nightly fasting plus telehealth coaching intervention (PNF+) versus healthy eati…
Men with prostate cancer on treatment safely tried nightly fasting and coaching, improving quality of life and showing slight weight loss wi…
Phase II RCT finds no benefit for adding capecitabine to 177Lu-Dotatate in advanced NETs
Adding a Drug Actually Hurted These Patients
A Phase II randomized controlled trial in 111 patients with advanced somatostatin receptor-positive GEP or bronchopulmonary NETs compared 17…
Adding a common chemotherapy drug to cancer treatment actually made tumors grow faster and reduced survival time for these patients.
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy in Chinese adults with advanced biliary tract carcinoma
Could adding pembrolizumab help Chinese adults live longer with advanced biliary tract carcinoma?
This phase 3 randomized controlled trial enrolled 158 Chinese adults with advanced or unresectable biliary tract carcinoma. The study compar…
A completed study in China compared adding pembrolizumab to chemotherapy for advanced bile duct cancer, tracking how long 158 adults survive…